Black Rock Inc. Cv Rx, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Cv Rx, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 764,999 shares of CVRX stock, worth $7.98 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

764,999

Previous 803,434 4.78%

Holding current value

$7.98 Million

Previous $25.3 Million 44.85%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$17.99 - $30.49 $691,445 - $1.17 Million	-38,435 Reduced 4.78%	764,999 $13.9 Million
Q4 2023 Feb 13, 2024	BUY	$11.67 - $33.01 $846,203 - $2.39 Million	72,511 Added 9.92%	803,434 $25.3 Million
Q3 2023 Nov 13, 2023	BUY	$13.56 - $18.47 $360,438 - $490,951	26,581 Added 3.77%	730,923 $11.1 Million
Q2 2023 Aug 11, 2023	BUY	$8.57 - $15.44 $5.51 Million - $9.93 Million	643,425 Added 1056.23%	704,342 $10.9 Million
Q1 2023 May 12, 2023	BUY	$7.08 - $19.4 $167,378 - $458,635	23,641 Added 63.42%	60,917 $567,000

Q4 2022 Feb 13, 2023	BUY	$10.07 - $18.35 $9,798 - $17,854	973 Added 2.68%	37,276 $684,000
Q3 2022 Nov 14, 2022	SELL	$6.12 - $9.5 $355,731 - $552,197	-58,126 Reduced 61.56%	36,303 $340,000
Q2 2022 Aug 12, 2022	SELL	$4.7 - $7.22 $1.43 Million - $2.2 Million	-305,216 Reduced 76.37%	94,429 $568,000
Q1 2022 May 12, 2022	BUY	$5.62 - $12.37 $23,789 - $52,362	4,233 Added 1.07%	399,645 $2.39 Million
Q4 2021 Feb 10, 2022	BUY	$10.65 - $18.61 $513,905 - $898,006	48,254 Added 13.9%	395,412 $4.84 Million
Q3 2021 Nov 09, 2021	BUY	$14.65 - $26.07 $5.09 Million - $9.05 Million	347,158 New	347,158 $5.74 Million

Others Institutions Holding CVRX

# of Institutions

Shares Held

13.8M

Call Options Held

264K

Put Options Held

89.3K

View Full List

About CVRx, Inc.

Ticker CVRX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 20,576,200
Market Cap $215M
Description
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The co...

More about CVRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account